Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,123
  • Shares Outstanding, K 45,656
  • Annual Sales, $ 3,670 K
  • Annual Income, $ -57,410 K
  • 60-Month Beta 1.48
  • Price/Sales 49.03
  • Price/Cash Flow N/A
  • Price/Book 1.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.28
  • Number of Estimates 6
  • High Estimate -0.21
  • Low Estimate -0.32
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.51 +8.97%
on 07/30/20
5.18 -26.16%
on 07/06/20
-1.16 (-23.35%)
since 07/02/20
3-Month
2.69 +42.19%
on 05/04/20
5.28 -27.56%
on 07/01/20
+1.11 (+40.63%)
since 05/01/20
52-Week
1.60 +139.06%
on 03/18/20
5.28 -27.56%
on 07/01/20
+0.42 (+12.50%)
since 08/02/19

Most Recent Stories

More News
Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 3.91 (+3.71%)
Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020

--Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020

APTX : 3.91 (+3.71%)
Aptinyx to be Added to Russell 2000(R) Index

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US...

APTX : 3.91 (+3.71%)
Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment...

APTX : 3.91 (+3.71%)
Aptinyx to Present at Upcoming Virtual Investor Conferences

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management...

APTX : 3.91 (+3.71%)
Is Aptinyx (APTX) Stock Outpacing Its Medical Peers This Year?

Is (APTX) Outperforming Other Medical Stocks This Year?

APTX : 3.91 (+3.71%)
Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the Upgrade

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

APTX : 3.91 (+3.71%)
Aptinyx's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aptinyx.

APTX : 3.91 (+3.71%)
Aptinyx Inc. (APTX) Reports Q1 Loss, Lags Revenue Estimates

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

APTX : 3.91 (+3.71%)
Aptinyx Reports First Quarter 2020 Financial Results and Highlights

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020

APTX : 3.91 (+3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade APTX with:

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

2nd Resistance Point 4.00
1st Resistance Point 3.88
Last Price 3.91
1st Support Level 3.70
2nd Support Level 3.64

See More

52-Week High 5.28
Last Price 3.91
Fibonacci 61.8% 3.87
Fibonacci 50% 3.44
Fibonacci 38.2% 3.01
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar